Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan

AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2

“…[24][25][26] However, a most recently published Chinese paper indicated a significant improved prognosis in t(8;21) AML-M2 patients treated with high-dose Ara-C. 27 These discrepancies might be ascribed to differences in treatment regimens, particularly the use of more intensive chemotherapy. [28][29][30] In this study, when analyzed according to treatment protocol, the adverse prognostic effect of AML1-ETO9a-H on EFS or OS was present in the standard Ara-C-based group but not in the median dose one, suggesting that the negative effect of AML1-ETO9a could be weakened by increased dose of Ara-C in the chemotherapy protocol. It is thus of great interest to conduct randomized clinical trial to confirm whether AML1-ETO9a could be further overcome by high-dose Ara-C consolidation.…”

Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes

“…Recent studies by others also suggested that prognosis of CBF AML could differ among different ethnic groups or races. 14,[35][36][37] The background molecular basis among the Japanese population must also be taken into account in future studies.…”

Clinical Characteristics of Acute Myeloid Leukemia with t(8;21) in Japan and Western Countries

“…As a result, the 3-year survival rate was 71%(n=35, patients with t(8;21)) and 58% (n=49, patients without t(8;21)), respectively, narrowing the difference, with no significant difference observed between the two groups. Furthermore, when prognosis factor analysis was conducted with all these patients as subjects, the presence of t(8;21) was not a significant prognosis factor (Narimatsu et al, 2008b). These results suggest that young age is the main reason for good prognosis in t(8;21)AML patients, which is very interesting.…”

“…The authors retrospectively investigated clinical features of 46 adult t(8;21)AML patients newly diagnosed at facilities participating in the research from 2000 to 2005 as the subjects (Narimatsu et al, 2008b). The comparison of its outcome with prior researches (Appelbaum et al, 2006;Marcucci et al, 2005;Nguyen et al, 2002;Schlenk et al, 2004) is shown in Table 1.…”

“…From these comparisons, it was suggested that the prognosis of Japanese t(8;21)AML patients was better than the prognosis of Westerners, and a possibility that racial differences may be involved as its cause, rather than the inclusion of background factors such as age and white blood cell count at initial visit, was suggested. The authors also compared the survival rate of t(8;21)AML patients and leukemia patients that were diagnosed in each institute at the same time as AML(M2) having no t(8;21) abnormality (Narimatsu et al, 2008b). As a result, the overall survival rate of t(8;21)AML patients was significantly better than AML(M2) patients without t(8;21) (70% vs. 43% for 3-year overall survival rate).…”